The Expanding Role of Therapeutic Antibodies

REFERENCES

• Winau F, Winau R. Emil von Behring and serum therapy. Microbes Infect 2002;4:185–188.
   PubMed Web of Science ®Google Scholar
• Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722–728.
   PubMed Web of Science ®Google Scholar
• Tiselius A, Kabat EA. Electrophoresis of immune serum. Science 1938;87:416–417.
   PubMedGoogle Scholar
• Cohn EJ, Luetscher JA Jr, Oncley JL, et al. Preparation and properties of serum and plasma proteins. J Am Chem Soc 1940;62:3396–3400.
   Google Scholar
• Stephan W. Undegraded human immunoglobulin for intravenous use. Vox Sang 1975;28:422–437.
   Google Scholar
• Eibl M. Treatment of defects of humoral immunity. Birth Defects Orig Artic Ser 1983;19:193–200.
   Google Scholar
• Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228–1231.
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–497.
   PubMed Web of Science ®Google Scholar
• Hooks MA, Wade CS, Millikan WJ Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 1991;11:26–37.
   PubMed Web of Science ®Google Scholar
• Raju TN. The Nobel chronicles. 1972: Gerald M Edelman (b 1929) and Rodney R Porter (1917–85). Lancet 1999;354:1040.
   PubMedGoogle Scholar
• Kistler P, Nitschmann H. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962;7:414–424.
   PubMed Web of Science ®Google Scholar
• Berger M. L-proline- stabilized human IgG: privigen 10% for intravenous use and Hizentra 20% for subcutaneous use. Immunotherapy 2011;3:163–176.
   PubMedGoogle Scholar
• Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006;6:592–599.
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012;367:2015–2025.
   PubMed Web of Science ®Google Scholar
• Quinti I, Pandolfi F, Paganelli R, et al. HCV infection in patients with primary defects of immunoglobulin production. Clin Exp Immunol 1995;102:11–16.
   Google Scholar
• Yu MW, Mason BL, Guo ZP, et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995;345:1173–1174.
   Google Scholar
• Dodd LG, McBride JH, Gitnick GL, et al. Prevalence of non-A,non-B hepatitis/hepatitis C virus antibody in human immunoglobulins. Am J Clin Pathol 1992;97:108–113.
   Google Scholar
• Durandy A, Kaveri SV, Kuijpers TW JV, et al. Intravenous immunoglobulins –understanding properties and mechanisms. Clin Exp Immunol 2009;158 (Suppl. 1):2–13.
   PubMed Web of Science ®Google Scholar
• Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006;6:535–542.
   PubMed Web of Science ®Google Scholar
• D'Amelio R, Palmisano L, Le Moli S, et al. Serum and salivary IgA levels in normal subjects: comparison between tonsillectomized and non-tonsillectomized subjects. Int Arch Allergy Appl Immunol 1982;68:256–259.
   PubMedGoogle Scholar
• Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986;314:560–564.
   PubMed Web of Science ®Google Scholar
• Schiff P, Kemp A. Safety of IVIG made from HCV-antibody-screened plasma Lancet 1991; 338:1076.
   Google Scholar
• Nydegger UW, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999;21:171–185.
   PubMed Web of Science ®Google Scholar
• Chan CEZ, Chan AHY, Hanson BJ, Ooi EE The use of antibodies in the treatment of infectious diseases. Singapore Med J 2009;50:663–673.
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Achuthanandam R, Capocasale RJ, et al. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 2009;5:499–521.
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S, et al. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N Engl J Med 2006;355:1018–1028.
   PubMed Web of Science ®Google Scholar
• Brown JM, Wilson TM, Metcalfe DD. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy 2008;38:4–18.
   PubMed Web of Science ®Google Scholar
• Brown SGA. Clinical features and severity grading of anaphylaxis. J All Clin Immunol 2004;114:371–376.
   PubMed Web of Science ®Google Scholar
• Brennan PJ, Rodriguez Bouza T, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J All Clin Immunol 2009;124: 1259–1266.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Maggi E, Matucci A Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol 2011;11:262–268.
   PubMed Web of Science ®Google Scholar
• Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007;28:313–319.
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008;358:1109–1117.
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. N Engl J Med 2012;366:1870–1880.
   PubMed Web of Science ®Google Scholar
• Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000;47:57–77.
   PubMed Web of Science ®Google Scholar
• Keller MA, Stiehm ER Passive Immunity in Prevention and Treatment of Infectious Diseases. Clin Microbiol Rev 2000;13:602–614.
   PubMed Web of Science ®Google Scholar
• Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006;354:462–471.
   PubMed Web of Science ®Google Scholar
• Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response. A public health strategy for a global challenge. JAMA 1997;278:433–435.
   PubMed Web of Science ®Google Scholar
• Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059–1070.
   PubMed Web of Science ®Google Scholar
• Stiehm ER, Orange JS, Ballow M, Lehman H, Therapeutic Use of Immunoglobulins. Adv Pediatr 2010;57:185–218.
   PubMedGoogle Scholar
• Ward R, Krugman S. Etiology, epidemiology and prevention of viral hepatitis. Prog Med Virol 1962;4:87–118.
   Google Scholar
• Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia with AIDS. Ann Intern Med 1990;113:926–933.
   PubMed Web of Science ®Google Scholar
• Angus PW, Patterson SJ. Liver Transplantation for Hepatitis B: What Is the Best Hepatitis B Immune Globulin/AntiviralRegimen? Liver Transplantation 2008;14:S15–S22.
   Google Scholar
• Lauchart W, Muller R, Pichlmayr R. Long- term immunoprophylaxis of hepatitis B virus (HBV) re-infection in recipients of human liver allografts. Transplant Proc 1987;19:4051–4053.
   PubMed Web of Science ®Google Scholar
• McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358–1364.
   PubMed Web of Science ®Google Scholar
• Von Hedenström M, Heberle U, Theobald K. Vaccination against tick-borne encephalitis (TBE): influence of simultaneous application of TBE immunoglobulin on seroconversion and rate of adverse events. Vaccine 1995;13:759–762.
   Google Scholar
• Cono J, Casey CG and Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR 2003;52(RR04);1–28.
   Google Scholar
• American Academy of Pediatrics. Smallpox (variola). In: Pickering LK, Baker CJ, Kimberlin DW, et al, editors. Red Book: 2009 Report of the Committee on infectious diseases. 28th edition. Elk Grove Village (IL): American Academy of Pediatrics; 2009. pp. 596–598.
   Google Scholar
• Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011;365:430–438.
   PubMed Web of Science ®Google Scholar
• Forthal DN, Landucci G. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J Immunol Methods 1998;220:129–138.
   PubMedGoogle Scholar
• Aschermann S, Lux A, Baerenwaldt A, et al. The other side of immunoglobulin G: suppressor of inflammation. Clin Exp Immunol 2010;160:161–167.
   Web of Science ®Google Scholar
• Negi VS, Elluru S, Sibéril S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007;27:233–245.
   PubMed Web of Science ®Google Scholar
• Tha-In T, Bayry J, Metselaar HJ, et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008;29:608–615.
   PubMed Web of Science ®Google Scholar
• Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011;127:315–323.
   PubMed Web of Science ®Google Scholar
• Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcg receptor antibody. N Engl J Med 1986;314:1236–1239.
   PubMed Web of Science ®Google Scholar
• Debre M, Bonnet MC, Fridman WH, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993;342:945–949.
   PubMed Web of Science ®Google Scholar
• Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729–1735.
   PubMed Web of Science ®Google Scholar
• Vassilev TL, Kazatchkine MD, Van Huyen JPD, et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 2004;93:3624–3631.
   Google Scholar
• Kazatchkine M, Kaveri S. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747–755.
   PubMed Web of Science ®Google Scholar
• Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990;85: 620–625.
   PubMed Web of Science ®Google Scholar
• Gupta M, Noel GJ, Schaefer M, et al. Cytokine modulation with immune g-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol 2001;21:193–199.
   PubMed Web of Science ®Google Scholar
• Leung DY. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin Exp Immunol 1996;104:49–54.
   Google Scholar
• Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by Staphylococcal toxin superantigens. J Clin Invest 1993;91:602–607.
   PubMed Web of Science ®Google Scholar
• Viard I, Wehrli P, Bullanim R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490–493.
   PubMed Web of Science ®Google Scholar
• von Gunten S, Yousefi S, Seitz M, et al. Siglec-9 transduces apoptotic and non-apoptotic death signals into neutrophils depending on the pro-inflammatory cytokine environment. Blood 2005;106:1423–1431.
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus 2009;18: 884–888.
   PubMed Web of Science ®Google Scholar
• Maddur MS, Othy S, Hegde P, et al. Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells. J Clin Immunol 2010;30(Suppl 1):S4–S8.
   PubMedGoogle Scholar
• Spahn JD, Leung DYM, Chan MTS, et al. Mechanisms of glucocorticoid reduction in asthmatics treated with intravenous immunoglobulin. J Allergy Clin Immunol 1999;103:421–426.
   Google Scholar
• Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008;359:307–309.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Ravecht V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313:670.
   PubMed Web of Science ®Google Scholar
• Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008;105:19571–19578.
   PubMed Web of Science ®Google Scholar
• Antony RM, Nimmerjahn, V, Ashline D, et al. Recapitulation of IVIg anti-Inflammatory activity with a recombinant IgG Fc. Science 2008;320:373.
   Google Scholar
• Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007;204:11–15.
   PubMed Web of Science ®Google Scholar
• Leong H, Stachnik J, Bonk ME, Matuszewski KA. Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm 2008;65:1815–1824.
   Google Scholar
• Ammann AJ, Ashman RF, Buckley RH, et al. Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol 1982;22:60–67.
   PubMedGoogle Scholar
• Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325:110–117.
   PubMed Web of Science ®Google Scholar
• Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985;64:145–156.
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C, Siegal FP, Smithwick EM, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984;101:435–439.
   PubMed Web of Science ®Google Scholar
• Quartier P, Debre M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999;134:589–596.
   PubMed Web of Science ®Google Scholar
• Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003;82:373–384.
   PubMed Web of Science ®Google Scholar
• Quartier P, Bustamante J, Sanal O, et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced cytidine deaminase deficiency. Clin Immunol 2004;110:22–29.
   PubMed Web of Science ®Google Scholar
• Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(suppl):S525–S553.
   Google Scholar
• Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997;131:47–54.
   PubMed Web of Science ®Google Scholar
• Litzman J, Jones A, Hann I, et al. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch Dis Child 1996;75:436–439.
   PubMed Web of Science ®Google Scholar
• de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 2000;20:77–82.
   PubMed Web of Science ®Google Scholar
• Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008;121:210–212.
   Google Scholar
• Lucas M, Lee M, Lortan J, Lopez-Granados E, et al. Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125:1354–1360.
   PubMed Web of Science ®Google Scholar
• Quinti I, Soresina A, Guerra A, et al. IPINet investigators. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011;31:315–322.
   PubMed Web of Science ®Google Scholar
• Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 2010;137:21–30.
   PubMed Web of Science ®Google Scholar
• Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes insubcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012;169:172–181.
   PubMed Web of Science ®Google Scholar
• Bonilla FA. Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes. Immunol Clin North Am 2008;28:803–819.
   PubMed Web of Science ®Google Scholar
• Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol 2007;122:146–55.
   PubMed Web of Science ®Google Scholar
• Gustafson R, Gardulf A, Hansen S, et al. Rapid subcutaneous immunoglobulin administration every secondweek results in high and stable serum immunoglobulin G levels inpatients with primary antibody deficiencies. Clin Exp Immunol 2008;152:274–279.
   PubMed Web of Science ®Google Scholar
• Thépot S, Malphettes M, Gardeur A, et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J Clin Immunol 2010;30:602–606.
   PubMed Web of Science ®Google Scholar
• Berger M. L-proline- stabilized human IgG: Privigen 10% for intravenous use and Hizentra 20% for subcutaneous use. Immunotherapy 2011;3:163–176.
   PubMedGoogle Scholar
• Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265–273.
   PubMed Web of Science ®Google Scholar
• Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010;30:734–745.
   PubMed Web of Science ®Google Scholar
• Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 1997;16:696–707.
   PubMed Web of Science ®Google Scholar
• Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988;319:902–907.
   PubMed Web of Science ®Google Scholar
• Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991;325:81–86.
   PubMed Web of Science ®Google Scholar
• The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;325:73–80.
   PubMed Web of Science ®Google Scholar
• Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988;109:777–782.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992;14:831–835.
   PubMed Web of Science ®Google Scholar
• Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995;16:393–399.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000;25:751–755.
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633–1639.
   PubMed Web of Science ®Google Scholar
• Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002;359:23–29.
   PubMed Web of Science ®Google Scholar
• Hedlund-Treutiger I, Henter JI, Elinder G. Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25:139–144.
   PubMedGoogle Scholar
• Cooper N. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia. Hematol Oncol Clin North Am 2009;23:1317–1327.
   PubMed Web of Science ®Google Scholar
• van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992;326:1123–1129.
   PubMed Web of Science ®Google Scholar
• Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225–230.
   PubMed Web of Science ®Google Scholar
• Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain- Barré syndrome. Neurology 1996;46:100–103.
   PubMed Web of Science ®Google Scholar
• van Doorn PA, Brand A, Strengers PF, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study. Neurology 1990;40:209–212.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838–845.
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119 (Suppl):1067–1077.
   Google Scholar
• Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445–449.
   PubMed Web of Science ®Google Scholar
• van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol 2002;1:491–498.
   PubMed Web of Science ®Google Scholar
• Ropper AH. Current treatments for CIDP. Neurology 2003;60(Suppl):S16–S22.
   Google Scholar
• van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005;CD004429.
   Google Scholar
• Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo- controlled study. Neurology 1994;44:429–432.
   PubMed Web of Science ®Google Scholar
• Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248–252.
   PubMed Web of Science ®Google Scholar
• Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256–1262.
   PubMed Web of Science ®Google Scholar
• Leger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145–153.
   PubMed Web of Science ®Google Scholar
• Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002;125:1875–1886.
   PubMed Web of Science ®Google Scholar
• van Doorn PA, van der Meche FG. IVIg treatment improves multifocal motor neuropathy: Easy to start but difficult to stop. Neurology 2000;55:1246–1247.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant 2011;11:196–202.
   PubMedGoogle Scholar
• Stiehm ER, Keller MA, Vyas GN. Preparation and use of therapeutic antibodies primarily of human origin. Biologicals 2008;36:363–374.
   Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993–2000.
   PubMed Web of Science ®Google Scholar
• Wang DX, Shu XM, Tian XL, et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: asystematic literature review. Clin Rheumatol 2012;31: 801–806.
   PubMed Web of Science ®Google Scholar
• Meissner M, Sherer Y, Levy Y, et al. Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int 2000;19:199–201.
   PubMed Web of Science ®Google Scholar
• Silvestris F, D'Amore O, Cafforio P, et al. Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clin Exp Immunol 1996;104(Suppl 1):91–97.
   Google Scholar
• Levy Y, Sherer Y, George J, et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999;119:231–238.
   PubMed Web of Science ®Google Scholar
• Lesprit P, Mouloud F, Bierling P, et al. Prolonged remission of SLE-associated polyradiculoneuropathy after a single course of intravenous immunoglobulin. Scand J Rheumatol 1996;25:177–179.
   PubMed Web of Science ®Google Scholar
• Aharon A, Levy Y, Bar-Dayan Y, Afek A, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997;6:408–411.
   PubMed Web of Science ®Google Scholar
• Aharon A, Zandman-Goddard G, Shoenfeld Y. Autoimmune multiorgan involvement in elderly men is it SLE? Clin Rheumatol 1994;13:631–634.
   PubMed Web of Science ®Google Scholar
• Piette JC, Lê Thi Huong D, Wechsler B. [Therapeutic use of intravenous immunoglobulins in the antiphospholipid syndrome]. Ann Med Interne (Paris) 2000;151(Suppl 1):1S51–S54.
   Google Scholar
• Savery F. Intravenous immunoglobulin treatment of rheumatoid arthritis-associated immunodeficiency. Clin Ther 1988;10:527–529.
   Google Scholar
• Ballow M. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 1991;68:1430–1436.
   PubMedGoogle Scholar
• Baleva M, Nikolov K. The role of intravenous immunoglobulin preparations inthe treatment of systemic sclerosis. Int J Rheumatol 2011;2011:829751.
   PubMedGoogle Scholar
• Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) 2008;87:10–20.
   PubMed Web of Science ®Google Scholar
• Jayne DR, Esnault VL, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993;6:207–219.
   Google Scholar
• Levy Y, George J, Fabbrizzi F, et al. Marked improvement of Churg–Strauss vasculitis with intravenous gammaglobulins. South Med J 1999;92:412–414.
   Google Scholar
• LeHoang P, Cassoux N, George F, et al. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm 2000;8:49–57.
   PubMed Web of Science ®Google Scholar
• Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997;349:589–593.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Wanscher B, Schreiber K, et al. A double blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results. Mult Scler 1997;3:145–148.
   PubMedGoogle Scholar
• Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998;50:398–402.
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629–632.
   PubMed Web of Science ®Google Scholar
• Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011:CD003279.
   Google Scholar
• Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490–493.
   PubMed Web of Science ®Google Scholar
• The INIS Collaborative Group: Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011;365:1201–1211.
   Google Scholar
• Berlot G, Vassallo MC, Busetto N, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care 2012;27:167–171.
   PubMed Web of Science ®Google Scholar
• Hoffman JN, Fertmann JM, Vollmar B, et al. Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia. Shock 2008;29:133–139.
   PubMedGoogle Scholar
• Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35:2677–2685.
   PubMed Web of Science ®Google Scholar
• Oesser S, Schulze C, Seifert J. Protective capacity of a IgM/IgA-enriched polyclonal immunoglobulin-G preparation in endotoxemia. Res Exp Med (Berl) 1999;198:325–339.
   Google Scholar
• Wesoly C, Kipping N, Grundmann R. Immunoglobulin therapy of postoperative sepsis. Z Exp Chir Transplant Kunstliche Organe 1990;23:213–216.
   PubMedGoogle Scholar
• Fillit H, Hess G, Hill J, et al. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009;73:180–185.
   PubMed Web of Science ®Google Scholar
• Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009; 30:1728–1736.
   PubMed Web of Science ®Google Scholar
• Loeffler DA. Intravenous immunoglobulin and Alzheimer's disease: What now? J Neuroinflammation. 2013;10:70. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• O'Nuallain B, Williams AD, McWilliams-Koeppen HP, et al. Anti-amyloidogenic activity of IgGs contained in normal plasma. J Clin Immunol 2010;30 (Suppl 1):S37–S42.
   Google Scholar
• Drucker NA, Colan SD, Lewis AB, et al. Gammaglobulin treatment of acute myocarditis in pediatric population. Circulation 1994;89:252–257.
   PubMed Web of Science ®Google Scholar
• Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001;103:220–225.
   PubMed Web of Science ®Google Scholar
• Schachter J, Katz U, Mahrer A, et al. Efficacy and safety of intravenous immunoglobulin in metastatic melanoma. Ann N Y Acad Sci 2007;1110: 305–314.
   PubMed Web of Science ®Google Scholar
• Murie-Fernández M, Gurpide A, de la Cruz S, de Castro P. Total remission of thymus carcinoma after treatment with intravenous immunoglobulin. Clin Transl Oncol 2006;8:697–699.
   Google Scholar
• Damianovich M, Solomon AS, Blank M, Shoenfeld Y. Attenuation of colon carcinoma tumor spread by intraveous immunoglobulin. Ann N Y Acad Sci 2007;1110:567–577.
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Mevorach D, Kaminski N, Raz E. Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis. Cancer 1994;73:2859–2861.
   Google Scholar
• Sapir T, Shoenfeld Y. Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. Clin Rev Allergy Immunol 2005;29:307–310.
   Google Scholar
• Shapiro S, Shoenfeld Y, Gilburd B, et al. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 2002;95:2032–2037.
   PubMedGoogle Scholar
• Fishman P, Bar-Yehuda S, Shoenfeld Y. IVIg to prevent tumor metastases (Review). Int J Oncol 2002;21:875–880.
   PubMedGoogle Scholar
• D'Ambrosio AL, Pinsky DJ, Connolly ES. The role of the complement cascade in ischemia/ reperfusion injury: Implications for neuroprotection. Mol Med 2001;7:367–382.
   PubMed Web of Science ®Google Scholar
• Arumugam TV, Tang SC, Lathia JD, et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A 2007;104:14104–14109.
   PubMed Web of Science ®Google Scholar
• Eftimov F, Vermeulen M, de Haan RJ, et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 2009;14:93–100.
   PubMed Web of Science ®Google Scholar
• Harbo T, Andersen H, Hess A, Hansen K, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009;16:631–638.
   PubMed Web of Science ®Google Scholar
• Lucas M, Hugh-Jones K, Welby A, et al. Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home. J Clin Immunol 2010;30 (Suppl 1):S84–S89.
   PubMedGoogle Scholar
• Lee DH, Linker RA, Paulus W, et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008;37: 406–409.
   PubMed Web of Science ®Google Scholar
• Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011;10:144–149.
   PubMed Web of Science ®Google Scholar
• Matucci A, Ravasio R, Vultaggio A, Maggi E. Analisi di minimizzazione dei costi della terapia con immunoglobuline (Ig) per il trattamento di pazienti con immunodeficienza primaria: confronto tra terapia con Ig sottocute vs endovena. HTA Giornale Italiano di Health Technology Assessment 2008;1:31–37.
   Google Scholar
• Johnston SL. Biologic therapies: what and when? J Clin Pathol 2007;60:8–17.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921–926.
   PubMed Web of Science ®Google Scholar
• Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002;130:93–100.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455–2466.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973–984.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985–993.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–659.
   Google Scholar
• Walsh GM. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther 2009;11:329–336.
   PubMed Web of Science ®Google Scholar
• Catley MC. Asthma & COPD–IQPC's Second Conference. I Drugs 2010;13:601–604.
   Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088–1098.
   PubMed Web of Science ®Google Scholar
• May RD, Monk PD, Cohen ES, et al. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol 2012;166:177–193.
   PubMed Web of Science ®Google Scholar
• A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility Source: EuCTR Trial Updates Record#2012–003351–11 [Sponsor:Amgen Inc.]
   Google Scholar
• St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451–1459.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Van Der Heijde DM, St Clair EW, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis Rheum 2006;54: 702–710.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Yocum D, Han J, et al. START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075–1086.
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912–920.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006;40:476–481.
   PubMed Web of Science ®Google Scholar
• Fur van der Heijde D, Dijkmans B, Geusens P, et al. Ankylosing spondylitis study for the evaluation of recombinant infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582–591.
   Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150–1157.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005;366:1367–1374.
   PubMed Web of Science ®Google Scholar
• Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti–tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563–2571.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35–45.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled. Arthritis Rheum 2004;50:1400–1411.
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508–516.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Goodman S, et al.: Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810–820.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 2005;52:3279–3289.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mease PJ, Thomson GT, et al. M02–570 Study Group. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040–1050.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH, et al. for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum 2006;54:2136–2146.
   PubMed Web of Science ®Google Scholar
• Lambert RG, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis. Arthritis Rheum 2007;56: 4005–4014.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323–333.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann Intern Med 2007;146:829–838.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63: 1200–1210.
   PubMed Web of Science ®Google Scholar
• Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129–1135.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Han C, Keystone EC, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: Results from the GO-FORWARD study. J Rheumatol 2012; 39: 1185–1191.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Landewé RB, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: Results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis 2012;71:1671–1679.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to TNF-α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: The GO-FORWARD study. Ann Rheum Dis 2009;68:789–796.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, et al. for the GO-AFTER study investigators Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210–221.
   PubMedGoogle Scholar
• Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:2272–2283.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor a antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Arthritis Rheum 2009;60:976–986.
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients With ankylosing spondylitis. Arthritis Rheum 2008;58:3402–3412.
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm352383.htm
   Google Scholar
• Keystone E, Heijde Dv, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319–3329.
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797–804.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–2806.
   PubMed Web of Science ®Google Scholar
• Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242–251.
   PubMed Web of Science ®Google Scholar
• Yamada H. Novel strategy for the treatment of refractory vasculitis syndrome. Ann Vasc Dis 2013;6:22–26.
   Google Scholar
• Kallenberg, CGM. Reclassification and the introduction of biological. Nat Rev Nephrol 2013;9:70–72.
   Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010;13: 246–252.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013;72:1026–1031.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. HERMES Trial Group. B cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676–688.
   PubMed Web of Science ®Google Scholar
• Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005;78:275–280.
   PubMed Web of Science ®Google Scholar
• Pertovaara M, Korpela M. Sustained response to rituximab in a patient with Sjögren's syndrome and severe refractory polyneuropathy. Clin Exp Rheumatol 2012;30:808.
   Google Scholar
• Yildirim-Toruner C, Diamond B. Current and Novel Therapeutics in Treatment of SLE. J Allergy Clin Immunol 2011;127:303–314.
   PubMed Web of Science ®Google Scholar
• Khanna D, Chong KK, Afifiyan NF, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2010;117:133–139.
   PubMed Web of Science ®Google Scholar
• Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443–1448.
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88–96.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609–621.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–999.
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968–2980.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–1523.
   PubMed Web of Science ®Google Scholar
• Imagawa T, Ozawa R, Miyamae T, et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyarticular course juvenile idiopathic arthritis with polyarticular or oligoarticular onset. Ann Rheum Dis 2007;66(Suppl II):550.
   Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998–1006.
   PubMed Web of Science ®Google Scholar
• http://www.medscape.com/viewarticle/803478
   Google Scholar
• http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000955/ smops/Positive/human_smop_000500.jsp&mid = WC0b01ac058001d127#key-facts
   Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385–2395.
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541–1550.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment):INNOVATE. Allergy 2005;60:309–316.
   PubMed Web of Science ®Google Scholar
• Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;2:CD003559.
   PubMedGoogle Scholar
• Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122:569–573.
   PubMed Web of Science ®Google Scholar
• Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567–573.
   PubMed Web of Science ®Google Scholar
• Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117:134–140.
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Zielen S, et al. DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2008;39:271–279.
   Google Scholar
• Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010;125: 383–389.
   PubMed Web of Science ®Google Scholar
• Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995;60:748–755.
   PubMed Web of Science ®Google Scholar
• Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997;350:1193–1198.
   PubMed Web of Science ®Google Scholar
• Kahan BD, Rajagopalan PR, Hall M, for the United States Simulect® Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999;67:276–284.
   PubMed Web of Science ®Google Scholar
• Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003;63:2803–2835.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–731.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–3930.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response. Ann Rheum Dis 2012;71:1343–1349.
   PubMed Web of Science ®Google Scholar
• Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med 2013;368:1528–1535.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416–2425.
   PubMed Web of Science ®Google Scholar
• Yasothan U, Kar S. Therapies for COPD. Nat Rev Drug Discov 2008;7:285.
   Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. PRINTO; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396–2406.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675–1684.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, et al. ACCEPT Study Group.Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118–128.
   PubMed Web of Science ®Google Scholar
• McInnes I, Kavanaugh A, Gottlieb A, et al. Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Ann Rheum Dis 2012;71:S107.
   Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis. N Engl J Med 2012;366:1181–1189.
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing MS. N Engl J Med 2006;354:899–910.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233–1243.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;111:1840–1847.
   PubMed Web of Science ®Google Scholar
• Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643–657.
   PubMed Web of Science ®Google Scholar
• Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169–2181.
   PubMed Web of Science ®Google Scholar
• D'Amelio R, Agostoni A, Biselli R, et al. Complement deficiency and antibody profile in survivors of meningococcal meningitis due to common serogroups in Italy. Scand J Immunol 1992;35: 589–595.
   Google Scholar
• Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011;11:2405–2413.
   PubMed Web of Science ®Google Scholar
• Morigi M, Galbusera M, Gastoldi S, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011;187:172–180.
   Google Scholar
• Phase 2 study of eculizumab (Soliris®) in patients with severe and refractory generalized myasthenia gravis presented at MGFR annual meeting. Cheshire, CT: Alexion Pharmaceuticals Inc. (press release); September 14, 2011.
   Google Scholar
• Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12(6):554–562.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan S, Lunn A, Kirschfink M, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012;366:1165–1166.
   PubMed Web of Science ®Google Scholar
• Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012;366:1161–1163.
   PubMed Web of Science ®Google Scholar
• Röth A, Hüttmann A, Rother RP, et al. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 2009;113:3885–3886.
   PubMed Web of Science ®Google Scholar
• Shapira I, Andrade D, Allen SL, Salmon JE. Induction of durable remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012;64:2719–2723.
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. EurJ Cancer 2001;37(Suppl 4):S3–S8.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39–51.
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Stockert E, Huang HJ, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 2003;100:639–644.
   PubMed Web of Science ®Google Scholar
• Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A 2007;104:4071–4076.
   PubMed Web of Science ®Google Scholar
• Vinochiani P, Hui KG, Scott AM. Antibodies in oncology. N Biotechnol 2011;28:518–529.
   Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317–327.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 2002;99:754–758.
   PubMed Web of Science ®Google Scholar
• Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789–1796.
   PubMed Web of Science ®Google Scholar
• Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122–1129.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317–327.
   PubMed Web of Science ®Google Scholar
• Pillay V, Gan HK, Scott AM. Antibodies in oncology. N Biotechnol 2011;28:518–528.
   Google Scholar
• Demarest SJ, Hariharan K, Dong J. Emerging antibody combinations in oncology. Mabs 2011;3:338–351.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Hx-CD20–406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453–2463.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918–3928.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579–4586.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cylophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Off ner F, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. Lancet 2010;377:42–51.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 235–242.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1756–1765.
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658–1664.
   PubMed Web of Science ®Google Scholar
• Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706–4713.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–578.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–1127.
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408–1417.
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040–2048.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539–1544.
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, et al. ML18147 Study Investigators Continuation of Bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29–37.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med 2006;355:2542–2550.
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103–2111.
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of Bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137–2143.
   PubMed Web of Science ®Google Scholar
• Moen MD. Bevacizumab: In previously treated glioblastoma. Drugs 2010;70:181–189.
   PubMed Web of Science ®Google Scholar
• Commissioner Statement. FDA Commissioner Removes Breast Cancer Indication from Avastin Label Date: November 18, 2011.
   Google Scholar
• www.ema.europa.eu/…/en_GB/document_library/EPAR__Product_Information/human/000582/ WC500029271.pdf
   Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of Bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484–2496.
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of Bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473–2483.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039–2045.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–1908.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388–1398.
   PubMed Web of Science ®Google Scholar
• Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010;340:c2459.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783–792.
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366–3373.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Roman JJ, et al. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 2008;102:128–131.
   PubMed Web of Science ®Google Scholar
• FDA approves new treatment for late stage breast cancer” [Press release]. U.S. Food and Drug Administration. 2013–02–22. Retrieved 2013–02–22.
   Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783–1791.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109–119.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–3561.
   Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Morris PJ, Russell NK. Alemtuzumab (Campath-1H): A Systematic Review in Organ Transplantation. Transplantation 2006;81:1361–1367.
   PubMed Web of Science ®Google Scholar
• MabCampath (alemtuzumab) Withdrawal of the marketing authorisation in the European Union 14 August 2012 EMA/532364/2012
   Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012;380:1819–1828.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012;380:1829–1839.
   PubMed Web of Science ®Google Scholar
• Sanofi (France) (SAN.PA)'s Lemtrada MS Drug Effective in Extension Trial 3/22/2013 7:11:42 AM
   Google Scholar
• Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209–2221.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28:5132–5139.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. A randomised, double-blind study of denosumab versus zoledronic acid in the treatment ofbone metastases in men with castration-resistant prostate cancer. Lancet 2011;377:813–822.
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. A randomized, double blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125–1132.
   PubMed Web of Science ®Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082–3092.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24:75–83.
   PubMed Web of Science ®Google Scholar
• Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis a hypophysitis. J Immunother 2007;30:825–830.
   PubMed Web of Science ®Google Scholar
• Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumorimmunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009;69:609–615.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase 2 study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183–2189.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: Results of a phase II study. J Clin Oncol 2012;30:2190–2196.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–133.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134–144.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–2465.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol 2011;29:369–377.
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854–4860.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terre' C, et al.: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet 2012;379:1508–1516.
   PubMed Web of Science ®Google Scholar
• Delaunay J, Recher C, Pigneux A, et al.: Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation: Results of the GOELAMS AML 2006 IR study. Blood 2011;118: (abstr 79).
   Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:3924–3931.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Estey EH, Appelbaum FR, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 2012;30:3291–3293; Becker H, Bloomfield CD. En route to improved treatment options. Nat. Rev. Clin. Oncol 2013;10:76–79.
   Google Scholar
• Rutgeerts P. on behalf of the GEMINI I working group. Vedolizumab maintenance therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter, phase 3 trial [abstract]. Gut 2012;61(Suppl. 3):A65.
   Google Scholar
• Colombel JF on behalf of the GEMINI II working group. Vedolizumab maintenance therapy for crohn's disease: results of GEMINI II, a randomized, placebo controlled, double- blind, multicenter, phase 3 trial [abstract]. Gut 2012;61(Suppl. 3):A32.
   Google Scholar
• Vermeire S, Rutgeerts P. Pathogenesis and management of IBD—thinking outside the box. Nat Rev Gastroenterol Hepatol 2013;10:67–69.
   Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;611:693–700.
   Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–765.
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Chapurlat R, Libanati C, et al. Bone HG. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res 2012;27:694–701.
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26: 4875–4882.
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745–755.
   PubMed Web of Science ®Google Scholar
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102:531–537.
   Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532–540.
   PubMed Web of Science ®Google Scholar
• Hu J, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: A systematic review. World J Pediatr 2010;6:296–300.
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 2006;295:1531–1538.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;5355:1419–1431.
   Google Scholar
• Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009;361:135–144.
   PubMed Web of Science ®Google Scholar
• van den Hoogen MWF, Hilbrands LB. Use of monoclonal antibodies in renal transplantation. Immunotherapy 2011;3:871–880.
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006;103:4005–4010.
   PubMed Web of Science ®Google Scholar
• Kubota T, Niwa R, Satoh M, et al. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009;100:1566–1572.
   PubMed Web of Science ®Google Scholar
• Berry JD, Gaudet RG. Antibodies in infectious diseases: Polyclonal, monoclonal and niche biotechnology. N Biotechnol 2011;28:489–495.
   PubMed Web of Science ®Google Scholar
• Luzi G, Diamanti AP, Germano V, et al. Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis. Clin Immunol 2007;125:127–130.
   PubMedGoogle Scholar
• Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Developing clinical guidelines. West J Med 1999;170:348–351.
   PubMedGoogle Scholar